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Abstract
The application of functionalized nanocarriers on photothermal therapy for cancer ablation
has wide interest. The success of this application depends on the therapeutic efficiency
and biocompatibility of the system, but also on the stability and biorecognition of the conju-
gated protein. This study aims at investigating the hypothesis that EGF functionalized poly-
mer-coated gold nanoparticles promote EGF photostability and EGFR internalization,
making these conjugated particles suitable for photothermal therapy. The conjugated gold
nanoparticles (100–200 nm) showed a plasmon absorption band located within the near-
infrared range (650–900 nm), optimal for photothermal therapy applications. The effects of
temperature, of polymer-coated gold nanoparticles and of UVB light (295nm) on the fluo-
rescence properties of EGF have been investigated with steady-state and time-resolved
fluorescence spectroscopy. The fluorescence properties of EGF, including the formation of
Trp and Tyr photoproducts, is modulated by temperature and by the intensity of the excita-
tion light. The presence of polymeric-coated gold nanoparticles reduced or even avoided
the formation of Trp and Tyr photoproducts when EGF is exposed to UVB light, protecting
this way the structure and function of EGF. Cytotoxicity studies of conjugated nanoparticles
carried out in normal-like human keratinocytes showed small, concentration dependent
decreases in cell viability (0–25%). Moreover, conjugated nanoparticles could activate and
induce the internalization of overexpressed Epidermal Growth Factor Receptor in human
lung carcinoma cells. In conclusion, the gold nanoparticles conjugated with Epidermal
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Growth Factor and coated with biopolymers developed in this work, show a potential appli-
cation for near infrared photothermal therapy, which may efficiently destroy solid tumours,
reducing the damage of the healthy tissue.
Introduction
Nanocarriers with improved characteristics, such as size, shape and plasmonic surface proper-
ties are selected for photonic therapeutic applications for cancer treatment [1]. One of the most
studied and potential application is the near-infrared (NIR) photothermal therapy based on
gold-nanoparticle-mediatedhyperthermia and, consequently, protein denaturation and tissue
necrosis [1]. As multifunctional system, nanocarriers are further functionalizedwith small tar-
geting peptides [2]. Therefore, the success of the photothermal therapy depends on the thera-
peutic efficiencyand biocompatibility of the system, but also on the stability and biorecognition
properties of the conjugated biomolecule.
Bio-functionalizationof nanoparticles with EGF has been applied to specific targeting cancer
cells, which overexpress EGFR and therefore, with ample interest for photothermal cancer treat-
ment. EGF offers many advantages for this type of pharmaceutical application: 1) EGF is smaller
(53 amino acids; MW: 6 kDa) than antibodies or other EGFR specific ligands used for the same
purpose; 2) unlike EGF, antibodies can trigger severe immune response leading to cytotoxicity
[1]; 3) EGF has three SS bonds, three Trp and five Tyr and hydrophobic residues, all suitable for
interactions with nanocarriers [3]; and 4) EGF is stable at physiological conditions and neutral
pH since its pI value is around 4.55, conferring the peptide a negative charge at pH> 7 [4]. Fou-
rier Transform Infrared (FT-IR) studies also showed that EGF presents a thermal unfolding at
pH 7.2 that starts at 40°C, with the transition midpoint at 55.5°C and complete denaturation is
observedabove 76°C [5]. Another study evaluated the application of EGF for skin patches,
showing the resistance of this peptide to temperature (Tm ~ 79°C) [6]. However, the potential
physiological activation and stimulation of cancer growth has hindered the use of EGF as target-
ing peptide in drug delivery systems, which is dependent on the release of the anticancer drug
[7]. When conjugated to metallic nanoparticles, EGF promotes a rapid internalization into can-
cer cells [8], and cancer destruction can be achieved by injecting the light-absorbing nanoparti-
cles locally and applying the laser-mediated hyperthermia directly into the tumour. Therefore, it
is our aim to use EGF-conjugated HAOA-coated gold nanoparticles with plasmon absorption
band located in the near-infrared (NIR) range (i.e., 650–900 nm), for photothermal therapy and
local hyperthermia, without damage to the surrounding tissues [9]. This study describes the
behaviour of EGF when exposed to temperature, UVB light (295 nm) and quenchers, such as
gold nanoparticles coated by hyaluronic and oleic acids (HAOA). The use of oleic acid (OA)
and polymers like hyaluronic acid (HA) can further promote the interaction and entrapment of
EGF onto gold nanoparticles, independently of the pI and pH of the solution, as previously
reported [10]. In addition, HA is described to be an excellent fluorescence quencher [11] and to
give structural stability to small proteins [12]. OA is also describedas a good protein fluores-
cence quencher [13]. The presence of quenchers shortens the fluorescence lifetimes and may
confer protection against photochemistry. Therefore, we have investigated if the presence of
gold nanoparticles coated with OA and HA protected the attached EGF fromUVwavelengths
normally used to trigger protein fluorescence, such as 295 nm.
UV excitation of proteins causes protein conformational changes upon excitation of the aro-
matic residues, i.e., tryptophan (Trp), tyrosine (Tyr) and phenylalanine (Phe). Three main
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photoproducts are kynurenine (Kyn, a photoproduct of Trp), N—formylkynurenine (NFK, a
photoproduct of Trp) and dityrosine (DT, a photoproduct of Tyr) [14–18]. Furthermore, UV
excitation of the side chains of aromatic residues induces the disruption of disulphide (SS)
bonds, mediated by an electron transfer process, leading to the formation of a transient disul-
phide electron adduct and to changes in the fluorescence quantum yield of proteins [16,17].
The effect of UV light on the structure and function of key medically relevant proteins, such as
Epidermal Growth Factor Receptor (EGFR) [19], insulin [14] and plasminogen [15] has been
reported.
The present study reports the time dependent effect of continuous 295 nm excitation of free
EGF on the peptide’s fluorescence emission intensity, as a function of irradiance level (power/
unit area) and temperature. Trp was selected as an intrinsic molecular probe and SYPRO1
Orange was used as an extrinsicmolecular probe in order to monitor protein conformational
changes [20]. The formation of photoproducts, NKF, Kyn and DT, has beenmonitored. More-
over, the expected protective effect provided by HAOA-coated gold nanoparticles against 295
nm-induced photochemistry on EGF was investigated by fluorescence spectroscopy and, struc-
turally, by circular dichroism spectroscopy. Binding of EGF and EGF-conjugated HAOA-
coated gold nanoparticles to EGFR, present on the cell membrane of A549 human lung carci-
noma cells, was monitored using confocal fluorescencemicroscopy and cytotoxicity assays
(MTT) were carried out in non-cancerous human immortalized keratinocytes,HaCaT cell line.
Materials and Methods
Materials
Gold (III) chloride trihydrate (HAuCl4) (PubChem ID: 24895143; Product number: G4022),
L-ascorbic acid (L-AA) (PubChem ID: 24891246; Product number: A7506), silver nitrate
(AgNO3) (PubChem ID: 24852543; Product number: S0139), hyaluronic acid (HA) sodium
salt from Streptococcus equi (MW: 7,000–250,000 g.mol-1) (PubChem ID: 24878223; Product
number: 53747), oleic acid (OA) (MW: 282.46 g.mol-1) (PubChem ID: 24886786; Product
number: 75090) were all supplied by Sigma-Aldrich (Steinheim, Germany). Recombinant
Human Epidermal Growth Factor (EGF) (PubChem ID: 62253638), Alexa Fluor1 647 and
SYPRO1 Orange Protein Gel Stain (5,000X Concentrate in DMSO) was purchased from Life
Technologies as molecular probes for confocal microscopy and protein conformational studies.
Primarymouse monoclonal antibody anti-EGFR neutralizer antibody LA1 was obtained from
Millipore (05–101). The water used for buffer preparation was purified through a Millipore
system. Thiazolyl Blue Tetrazolium Bromide (MTT), Fetal Bovine Serum (FBS), puromycin
and penicillin/streptomycin were supplied by Sigma-Aldrich (Steinheim, Germany), as of cell
culture grade. Dulbecco'sModified Eagle'smedium (DMEM) was supplied by Biowest (Nuaillé,
France) and DMSO was supplied by Merck (Darmstadt, Germany).
Preparation of EGF stock solution and EGF-conjugated gold
nanoparticles
A 2.5 μM (16.5 μg/mL) stock solution of EGF was prepared in 2 mM Phosphate Buffer Saline
(PBS) at pH 7.4. In order to prepare EGF-conjugated gold nanoparticles, the EGF stock solu-
tion at 2.5 μM was mixed with the gold nanoparticles solution (0.22 mM) and hyaluronic acid-
oleic acid (HAOA) solution (1 mg/mL), at a 1:1 (v/v) ratio. The reactionmixture was kept for
30 min at room temperature and, then, left overnight at 4°C protected from the light. Gold
nanoparticles were produced based on the addition of an aqueous extract of Plectranthus sacca-
tus (10 mg/ mL) as the main reducing and capping agent [21]. The aqueous plant extract was
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used in alternative to cetyl trimethylammonium bromide (CTAB), and prepared according to
the procedure describedby Rijo et al. (2014), using a microwave method [22]. The nanoparti-
cles suspension was centrifuged twice at 500 x g for 20 min in a FV2400Microspin (BioSan,
Riga, Latvia) to remove unbound peptides. The pellet was re-suspended in PBS buffer (pH 7.4).
EGF stock solution was stored at -20°C until further use.
EGF structure analysis and gold nanoparticles structure design
Crystallographicdata used for the display of the 3D protein structure (Fig 1) was extracted from
1JL9.pdb (3D structure of EGF, chain B), using Discovery Studio 4.1 (Accelrys Software, San
Diego, CA, USA). Distances between protein residues were obtained by using the monitor tool
Fig 1. Molecular structure of EGF (chain B) according to (1JL9.pdb). Aromatic residues are represented
by different colors: Trp (red), Tyr (blue), Cys (green).
doi:10.1371/journal.pone.0165419.g001
Table 1. Shortest spatial distances between disulphide (SS) bonds and aromatic residues (trypto-
phan and tyrosine) in EGF chain B (1JL9.pdb). The shortest distances (< 12 Å) between atoms of each
pair of elements (Trp, Tyr and disulphide bonds) were considered. For Trp and Tyr residues, only atoms
belonging to the indole and benzene rings were considered, and for SS bonds one of the SG atoms.
(W = Trp; Y = Tyr; PDB atomtype descriptor used is given in parentheses).
Disulphide Bond Aromatic Residue Distance (Å)
C6-C20 Y13 (CD1) 5.5
Y22 (CG) 9.2
Y29 (CD1) 4.8
C14-C31 Y13 (CD1) 4.4
Y29 (CD1) 9.5
Y37 (CD2) 9.7
Y44 (CD2) 11.8
C33-C42 Y13 (CD1) 7.9
Y37 (CG) 5.7
Y44 (CD2) 9.5
W49 (CZ3) 7.3
doi:10.1371/journal.pone.0165419.t001
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in the program (Table 1). Adobe Illustrator CS5 (Adobe Systems Software Ireland Ltd.) was
used in order to graphically display the EGF-conjugated HAOA-coated gold nanoparticles.
Steady-state fluorescence spectroscopy studies
Steady-state fluorescence emission spectra were collected upon excitation of the Trp pool of
the protein at 295 nm. Excitation spectra were acquired with emission wavelength at 330 nm.
All measurements were conducted on a fluorescence RTC 2000 spectrometer (Photon Tech-
nology International, Canada, Inc.347 ConsortiumCourt London, Ontario N6E 2S8) with a T-
configuration, using a 75-W Xenon arc lamp coupled to a monochromator. Samples were ana-
lyzed in quartz high precision cell with 10 cm x 2 cm of light path (Hellma Analytics) and
gently shaken before each measurement. All slits were set to 5 mm.
Continuous 295 nm illumination of EGF
Temperature effect on EGF photochemistry. Continuous 295 nm illumination of EGF
(fresh sample, 2.5 μM) was carried out for 2 hours and the protein’s fluorescence emission
intensity at 330 nm was monitored at five different temperatures: 10°C, 15°C, 20°C, 25°C and
30°C (Fig 2). Excitation slit was set at 0.8 mm, with an equivalent lamp power of 1.67 μW.
Fresh samples were used for each experiment. Emission and excitation intensity spectra were
corrected in real-time for oscillations in the emission intensity of the excitation lamp. The
Arrhenius plot for free EGF was also represented and all parameters calculated, as explained
further in the “Data analysis” section (Fig 3).
Light power effect on EGF photochemistry. Continuous 295 nm illumination of EGF
(fresh sample, 2.5 μM) was carried out for 2 hours and the peptide’s fluorescence emission
intensity at 330 nm was monitored using different excitation slit openings: 0.1 mm, 0.5 mm,
0.8 mm, 1.2 mm and 2.0 mm corresponding to 0.12 μW, 0.30 μW, 1.67 μW, 2.34 μW and
4.40 μW, respectively (Fig 4). Fluorescence excitation (em. fixed at 330 nm) and emission (exc.
fixed at 295 nm) spectra of EGF were acquired before and after each EGF illumination using
different excitation slit openings. The excitation slit size versus excitation power was deter-
mined by measuring the power level at the cuvette location with a power meter (Ophir Photon-
ics StarLite Meter ASSY ROHS, P/N7Z01565, Jerusalem, Israel) and a power head (Ophir
Photonics, 30A-BB-18 ROHS, P/N7Z02692, Jerusalem, Israel) upon varying the excitation slit
size, as previously reported for lysozyme [23]. The temperature of the solution was kept at
20°C using a Peltier element at the cuvette holder location. A fresh sample was used for each
illumination session.
SYPRO1 Orange: probing EGF conformation changes induced by 295 nm and tempera-
ture. SYPRO1 Orange is used as a molecular probe in order to monitor protein conforma-
tional changes since its fluorescence is greatly enhanced upon contact with hydrophobic
environments [24]. A 2 μL aliquot (dilution 1:1000) of SYPRO1 Orange stock solution
(5,000X Concentrate in DMSO) was added to a cuvette containing a fresh sample of EGF
(2.5 μM, 0.2 mL) prior to the 295 nm continuous illumination experiment. The sample was
gently shaken to mix both solutions. Fluorescence emission of SYPRO1 Orange at 580 nm was
monitored upon continuous illumination at 470 nm for 2 hours, at each of the above men-
tioned temperatures, i.e., 10°C, 15°C, 20°C, 25°C and 30°C. Fluorescence intensity changes
were quantified. In addition, the fluorescence emission of SYPRO1 Orange at 580 nm was
monitored upon continuous illumination at 470 nm for 2 hours, at each of the above men-
tioned power levels, i.e., 0.12 μW, 0.30 μW, 1.67 μW, 2.34 μW and 4.40 μW (corresponding
to 0.1 mm, 0.5 mm, 0.8 mm, 1.2 mm and 2.0 mm slits, respectively). Fluorescence spectral
changes were quantified.
EGF Functionalized Nanoparticles for Photothermal Therapy
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Photoproducts of tryptophan and tyrosine. Fluorescence excitation and emission spectra
of the Trp and Tyr photoproducts (e.g., NFK, Kyn and DT) were monitored. Excitation and
emission fluorescence spectra of the photoproducts differ from the ones of Trp and Tyr: NFK
and Kyn are excited at 320 nm and 360 nm and show a maximum emission between 400–440
nm and between 434–480 nm, respectively [25–27]. Therefore, EGF fluorescence intensity
changes and spectral shifts were quantified, before and after the illumination of EGF at 295
nm, at different temperatures and different light power slit openings.
Photochemistryof EGF conjugated with HAOA-coated gold nanoparticles. The effect
of continuous 295 nm excitation of EGF has been investigated for EGF conjugated to gold
nanoparticles covered by natural polymers, such as hyaluronic acid (HA) and oleic acid
(OA) (Fig 5). Results were compared with data obtained with free EGF. Four samples were
continuously illuminated with 295 nm light for 2 hours at 20°C and their fluorescence emis-
sion intensity at 330 nm has beenmonitored: a) free EGF, b) EGF-conjugated HAOA-coated
nanoparticles, c) plain non-coated gold nanoparticles and d) HAOA coated-gold nanoparti-
cles (Fig 6). Excitation slit was set to 2.0 mm, with an equivalent power of 4.40 μW at the
entrance of the excitation chamber. Conjugation of EGF onto the HAOA-coated gold
Fig 2. Temperature effect on EGF photochemistry: A) EGF fluorescence excitation and emission
wavelengths were fixed at 295 nm and 330 nm, respectively, at 10˚C, 15˚C, 20˚C, 25˚C and 30˚C; B)
SYPRO® Orange fluorescence excitation and emission wavelengths were fixed at 470 nm and 580
nm, at the same temperatures. Continuous illumination was conducted during 2 hours and the excitation
slit size was set at 0.8 mm (1.67 μW) for all experiments.
doi:10.1371/journal.pone.0165419.g002
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nanoparticles has been confirmed using steady state fluorescence spectroscopy. Fluorescence
excitation (em. fixed at 330 nm) and emission (exc. fixed at 295 nm) spectra of non-conju-
gated EGF, of the supernatant after centrifugation of the solution containing conjugated and
non-conjugated EGF, and of conjugated EGF onto HAOA-coated gold nanoparticles, have
been acquired in order to detect the presence of protein (Fig 7). In order to detect likely light-
induced conformational changes in EGF, SYPRO1 Orange was used as a molecular probe.
Fluorescence emission spectra of SYPRO1 Orange (excitation fixed at 470 nm) and fluores-
cence excitation spectra of SYPRO1 Orange (emission fixed at 580 nm) were also acquired
prior and after continuous illumination of EGF and EGF-conjugated HAOA-coated gold
nanoparticles at 295 nm for 2 hours (Figs 8 and 9). Formation of Trp photo products (Kyn
and NFK) upon 295 nm excitation of free EGF and EGF-conjugated HAOA-coated gold
nanoparticles has been confirmed using steady state fluorescence spectroscopy (Fig 10). In
order to detect Kyn and NFK, fluorescence emission spectra were acquired upon 320 nm
excitation of the solution before and after 2 hours of continuous illumination at 295 nm. In
order to detect the presence of Kyn, emission spectra were obtained upon 360 nm excitation
before and after 295 nm continuous excitation. Fluorescence spectral changes have been
quantified and compared for free and conjugated EGF. A fresh sample was used for each illu-
mination run.
Fig 3. Arrhenius plot showing the linear correlation between the logarithm of the kinetic rate
constant (ln k) and the inverse of temperature 1/T (ln k = ln A0—Ea/RT), R2 = 0.994). The activation
energy (Ea) and the pre-exponential factor (A0) were 19.9±0.9 kJ.mol-1 and 0.44±0.37 M-1.s-1, respectively.
Uncertainty errors for ln k values are represented as error bars (percent of data: 1%).
doi:10.1371/journal.pone.0165419.g003
EGF Functionalized Nanoparticles for Photothermal Therapy
PLOS ONE | DOI:10.1371/journal.pone.0165419 October 27, 2016 7 / 29
Physical characterization of EGF-conjugated HAOA-coated gold
nanoparticles
Mean particle size, polydispersity index (PI) and zeta potential (ZP) for EGF-conjugated
HAOA-coated gold nanoparticles were determinedwith a Coulter Nano-sizer Delsa Nano™C
(Fullerton, CA). A low value of PI factor (< 0.25) will indicate a less dispersed nanoparticles
distribution in size. “D-value” was determined as the size distribution in 10%, 50% and 90% of
the nanoparticles population [28]. EGF-conjugated HAOA-coated gold nanoparticles were
characterized by UV-visible spectroscopy (Evolution 600, UK) and the respectivemaximum
absorbance wavelength (λmax) was determined.
TEM analysis of EGF-conjugated HAOA-coated gold nanoparticles
Structure and surface morphology of EGF-conjugated HAOA-coated gold nanoparticles were
analyzed by Transmission ElectronMicroscopy (TEM, ZeissM10, Germany) (Fig 5). Samples
were prepared through “sequential two-droplet” method by re-suspending the nanoparticles in
distilledwater and placing a drop (5–10 μL) of the suspension on to a formvar grid for 30–60
Fig 4. UV-light power effect (different excitation slit openings) on EGF photochemistry: A) EGF
fluorescence excitation and emission wavelengths were fixed at 295 nm and 330 nm, respectively,
for 0.1 mm (0.12 μW), 0.5 mm (0.30 μW), 0.8 mm (1.67 μW), 1.2 mm (2.34 μW) and 2.0 mm (4.40 μW); B)
SYPRO® Orange fluorescence excitation and emission wavelengths were fixed at 470 nm and 580
nm, for the same power levels. Continuous illumination was conducted during 2 hours and the temperature
of each solution was kept at 20˚C for all experiments.
doi:10.1371/journal.pone.0165419.g004
EGF Functionalized Nanoparticles for Photothermal Therapy
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sec.When the nanoparticles suspension had partly dried, the surface of the grid was washed
three times with distilledwater and the excess of water was removed with a filter paper. Then,
sodium phosphotungstate (PTA, 2%, w/v) was applied to the grid for 10 sec, the excess of stain
removed with a filter paper and the grid was left to dry at room temperature for 24 hours. Sam-
ples were analyzed at voltage setting of 10–20 kV. Different fields of the images were recorded
digitally.
Confocal fluorescence microscopy studies with EGF-conjugated HAOA-
coated gold nanoparticles
EGF-conjugated HAOA-coated gold nanoparticles were marked with two different fluorescent
probes, Coumarin-6 and Alexa Fluor 647, as describedbelow, for confocalmicroscope visualiza-
tion and colocalization (Fig 11). Firstly, an aliquot (20 μL) of a saturated solution of Coumarin-
6 (λmax_ex = 460 nm, λmax_em = 500 nm) in ethanol was added to an aqueous suspension, con-
taining the polymer HAOA and the gold nanoparticles at 1:1 (v/v). Then, EGFmarked with
Alexa Fluor 647 (λmax_ex = 650 nm, λmax_em = 665 nm) was added to the HAOA-coated gold
nanoparticles suspension. Coumarin-6 labeled nanoparticles were allowed to conjugate with the
EGF-Alexa Fluor 647 for 30 min at room temperature, and were left 24 hours at 4°C, protected
from the light. The suspension was centrifuged twice at 500 x g for 20 min in a FV2400Micro-
spin (BioSan, Riga, Latvia) to remove unbound EGF. The pellet was re-suspended in PBS buffer
(pH 7.4). Confocal Laser ScanningMicroscopy (CLSM, Leica, SP5, Mannheim, Germany) was
used to verify the colocalization of both dyes on the EGF-conjugated HAOA-coated gold nano-
particles. The chosen excitation laser line He-Ne was 561 nm and the fluorescence emission
Fig 5. EGF conjugated HAOA-coated gold nanoparticles represented as an illustration (upper
corner) and as the TEM image at scale bar of 250 nm.
doi:10.1371/journal.pone.0165419.g005
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Fig 6. EGF fluorescence emission intensity at 330 nm for free EGF (2 hours 295 nm excitation), EGF-conjugated
HAOA-coated gold nanoparticles (2 hours 295 nm excitation), and empty HAOA-coated gold nanoparticles and
non-coated plain gold nanoparticles (1 hour 295 nm excitation). All samples were analyzed at 20˚C and excitation
slit size fixed at 2.0 mm (4.40 μW).
doi:10.1371/journal.pone.0165419.g006
Fig 7. A) Conjugation effect: EGF in supernatant (after conjugation) compared with free EGF and
EGF-conjugated HAOA-coated gold nanoparticles; B) EGF-conjugated HAOA-coated gold
nanoparticles, at different scale bar. Fluorescence excitation spectra was fixed at 330 nm and
fluorescence emission spectra was fixed at 295 nm. Experiments were conducted at 20˚C and excitation slit
size fixed at 2.0 mm (4.40 μW). No continuous excitation of EGF was conducted, beside the necessary for
obtaining the represented spectra.
doi:10.1371/journal.pone.0165419.g007
EGF Functionalized Nanoparticles for Photothermal Therapy
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selected range was set to 569–666 nm. Each sample was analyzed at room temperature and
upon letting it dry on a glass slide. Different fields of the images were recorded digitally.
Circular dichroism spectroscopy
Far UV circular dichroism (CD) spectroscopy was carried out to detect any changes in EGF
secondary structure after conjugation with HAOA-coated gold nanoparticles using a Jasco J-
Fig 8. EGF fluorescence excitation and emission spectra acquired before and after 295 nm
illumination for 2 hours. Trp fluorescence excitation and emission wavelengths were fixed at 295 m and
330 nm, respectively. Excitation slit size was set at 2.0 mm (4.40 μW) and the temperature of each solution
was kept at 20˚C for all experiments.
doi:10.1371/journal.pone.0165419.g008
Fig 9. SYPRO® fluorescence excitation and emission spectra acquired before and after EGF 295 nm
illumination for 2 hours. SYPRO® Orange fluorescence excitation and emission wavelengths were fixed at
470 nm and 580 nm, respectively. Excitation slit size was set at 2.0 mm (4.40 μW) and the temperature of
each solution was kept at 20˚C for all experiments.
doi:10.1371/journal.pone.0165419.g009
EGF Functionalized Nanoparticles for Photothermal Therapy
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Fig 10. A) Fluorescence emission spectra for NFK + Kyn, before and after excitation of free EGF and EGF-
conjugated HAOA-coated gold nanoparticles, at a fixed wavelength of 320 nm. Experiments were conducted
at 20˚C and excitation slit size fixed at 2.0 mm (4.40 μW); B) Fluorescence emission spectra for Kyn + NFK,
before and after excitation of free EGF and EGF-conjugated HAOA-coated gold nanoparticles, at a fixed
wavelength of 360 nm. Experiments were conducted at 20˚C and excitation slit size fixed at 2.0 mm
(4.40 μW).
doi:10.1371/journal.pone.0165419.g010
Fig 11. Colocalization of HAOA-coated gold nanoparticles conjugated with EGF. EGF was dyed with
Alexa Fluor 647 (red color) and HAOA-coated gold nanoparticles were dyed with Coumarin-6 (green color).
The parts were the HAOA-coated gold nanoparticles are associated with EGF, in the same localization, are
visible in yellow (scale bar at 5 μm).
doi:10.1371/journal.pone.0165419.g011
EGF Functionalized Nanoparticles for Photothermal Therapy
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720 spectropolarimeter (Jasco Corporation, Easton, MD, USA), with a photomultiplier suitable
for the 200–700 nm range (Fig 12). After calibration to remove the noise of the device, the PBS
buffer used to prepare the native EGF solution andMilli-Qwater used for nanoparticles formu-
lations were used as references to obtain the respective baselines. Far UV spectra were acquired
using a quartz cell containing solutions of free EGF (0.3 mg/mL), EGF-conjugated HAOA-
coated gold nanoparticles (16.5 μg/mL) and HAOA-coated gold nanoparticles (without pep-
tide). Furthermore, spectra of EGF extracted fromHAOA-coated gold nanoparticles by two
different methods were recorded: 1) EGF non-conjugated present in the supernatant after cen-
trifugation of EGF-conjugated HAOA-coated gold nanoparticles at 7200 x g for 10 min and 2)
after incubation of EGF-conjugated HAOA-coated gold nanoparticles in PBS pH 5.5, at 37°C,
for 72 hours, followed by centrifugation at 9000 x g for 3 min. Scanning of each sample was
conducted from 200 nm to 260 nm with a resolution of 1 nm band width, 3 accumulations,
scan speed 100 nm/min and 2 seconds response time. Data was processed using 10 point
smoothing in Origin 8.1 (OriginLabCorporation,Northampton, MA, USA).
Cytotoxicity assays in HaCaT cell line model
Cell viability studies were conducted in human immortalized keratinocytes (HaCaT, CLS Cell
Lines ServiceGmbH, Epplheim, Germany) using the MTT assay [29, 30] in order to assess the
cytotoxicity of EGF-conjugated HAOA-coated gold nanoparticles (Fig 13). Cells were cultured
in Dulbecco’s Modified EagleMedium (DMEM) medium supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin solution. HaCaT cells were seeded onto 96-well
Fig 12. The CD spectra of: free EGF (0.3 mg/mL), HAOA coated gold nanoparticles (without EGF),
EGF-conjugated HAOA coated gold nanoparticles (16.5 μg/mL), non- conjugated EGF in
supernatant, extracted by centrifugation, and EGF extracted after incubation of EGF-conjugated
HAOA coated gold nanoparticles in phosphate buffer pH 5.5, at 37˚C, for 72 hours.
doi:10.1371/journal.pone.0165419.g012
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plate at a density of 5,000 cells/ well to reach the desired confluence. EGF-conjugated HAOA-
coated gold nanoparticles were tested at different concentrations: 0–80 μM (based on the con-
centration of gold). DMSO 5% (v/v) was used as the positive control. Cells were exposed to
nanoparticles for 24 hours. After this period, the cells were washed twice with PBS and incu-
bated with MTT solution (0.5 mg/mL in culture medium) for 2.5 hours at 37°C. Culture
mediumwas then removed and cells were washed again with PBS. DMSO (200 μL per well)
was added to dissolve the formazan crystals and absorbance was read at 595 nm (Thermo Sci-
entificMultiskan FC, Shanghai, China). Three to four independent experiments were carried
out, each comprising four replicate cultures.
EGFR binding assay on A549 cells GFP-EGFR
In vitro studies were carried out in A549 cells, in which the genomic EGFR gene has been
endogenously tagged with a Green Fluorescent Protein gene (GFP) (Sigma-Aldrich ref.
CLL1141), since this is a specific and well-studied cell model for EGFR binding assay [30].
A549 cells were cultured in DMEMmedium + FBS 10% and 1 μg/mL puromycin and main-
tained at a 37°C in a 5% CO2 atmosphere, in order to analyze the effects of adding free EGF
(4 μg/mL), EGF-conjugated HAOA-coated gold nanoparticles (4 μg/mL EGF; 60 μM gold
nanoparticles) and HAOA-coated gold nanoparticles (non-conjugated; 60 μM). EGF-conju-
gated HAOA-coated gold nanoparticles were marked with two different fluorescent probes,
Coumarin-6 (λmax_ex = 460 nm, λmax_em = 500 nm) and Alexa Fluor 647 (λmax_ex = 650 nm,
λmax_em = 665 nm), as previously described, for confocal microscope visualization and colocali-
zation experiments (Fig 14). Free EGF was marked with Alexa Fluor 647, while nanoparticles
Fig 13. Viability (%) of HaCaT cells exposed to EGF-conjugated HAOA-coated gold nanoparticles for
24 hours, assessed by MTT assay (n = 3–4; mean ± SD).
doi:10.1371/journal.pone.0165419.g013
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were labeled with Coumarin-6. Prior to the image acquisition in the confocal fluorescence
microscope, the cells were incubated 1.5 hours with the free EGF and with the EGF-conjugated
HAOA-coated gold nanoparticles. In some wells, a primarymouse monoclonal antibody anti-
EGFR (1 μg/mL of neutralizer antibody LA1, Millipore (05–101)) was used to block EGFR.
After 1 hour of incubation with the antibody, free EGF or EGF-conjugated HAOA-coated gold
nanoparticles were added to the A549 cells’ incubationmedium, for incubation during 1.5
hours, to see if they compete for the receptor binding and consequent receptor internalization.
As controls, non-treated cells and HAOA-coated gold nanoparticles loaded with Coumarin-6
(without EGF) were used. EGFR binding and activation was analyzed by confocal fluorescence
microscopy (CLSM, Leica, SP5, Mannheim, Germany). Ligand binding to EGFR activates
the receptor and the GFP tagged receptor initially localized on the cell membranes, is then
internalized. This leads to the appearance of fluorescence granules in the cell cytoplasm, as
Fig 14. EGFR binding assay in A549 cell model, for 1.5 hours in contact with treatment (100X). CN1
corresponds to the non-treated cells, while CN2 shows the exposure to HAOA-coated gold nanoparticles
(without any dye). As for the treatment groups: A1) free EGF with Alexa Fluor 647, B1) EGF-conjugated
HAOA-coated gold nanoparticles (only EGF is marked with Alexa Fluor 647), and C1) EGF-conjugated
HAOA-coated gold nanoparticles (both EGF and HAOA-coated gold nanoparticles are marked with Alexa
Fluor 647 and Coumarin-6, respectively). For A2, B2 and C2, anti-EGFR antibodies were added 1 hour
before the addition of the tested samples.
doi:10.1371/journal.pone.0165419.g014
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describedpreviously for Human EGFR Live Cell Fluorescent Biosensor Assay (Sigma-Aldrich,
Germany).
Data Analysis
All data analysis, plotting and fitting procedures were done using Origin 8.1 (OriginLabCorpo-
ration, Northampton, MA, USA).
Emission Spectra and Excitation Spectra. Emission and excitation spectra were first
smoothed using a 10 points adjacent averaging. All fluorescence spectra obtained were first
Raman corrected by subtracting the spectra recorded for the buffer in solution. Normalized
emission and excitation spectra were obtained by dividing each data point by the maximum
intensity value in each spectrum.
Fitting Procedures
EGF fluorescenceemission kinetic traces (em. at 330 nm) upon 295 nm continuous exci-
tation as a function of light power and temperature. Each decay curve acquired upon 2
hours of continuous 295 nm illumination of EGF exposed at different temperatures (10°C,
15°C, 20°C, 25°C and 30°C) and different excitation slit openings (0.5 mm, 0.8 mm, 1.2 mm
and 2.0 mm), was fitted using a single exponential decay model given by the function F(t) =
C1exp(-xk1) + y0 or a double exponential decay model, according to F(t) = y0+C1exp(-k1x)
+C2exp(-k2x). F(t) is the fluorescence emission intensity at 330 nm (a.u.) upon 295 nm at
excitation time t (min), y0, C1 and C2 are constants and k1, k2 are the rate constant of fluores-
cence emission intensity decrease (min-1); y0 value was fixed to 0. Root mean square error R2
was> 0.99 for all fitted traces. A double exponential decay model was selected if the single
decay model did not provide a good fit. Data obtained with 0.1 mm slit size, was fitted using a
linear model (F(t) = y0+C1x). A good fit was based on the errors associated to the different
parameters and the root mean square error. Fitted parameter values and corresponding errors,
and root mean square error values obtained after fitting the 330 nm emission kinetic traces are
displayed in Tables 2 and 3.
EGF photochemistry:Arrhenius plot and activation energy. Temperature dependence
of the decay constant of the EGF kinetic traces (Fig 2A) (where the fluorescence emission
intensity at 330 nm is displayed upon 295 nm excitation), was analyzed using four different
temperatures: 15°C, 20°C, 25°C and 30°C. Data was fitted according to the logarithmic form of
the Arrhenius equation: ln k = ln A0 + (Ea/RT), whereA0 is the pre-exponential factor, Ea is the
activation energy, R is the universal constant for perfect gases (R = 8.314 J/ mol.K) and T is the
temperature (in Kelvin). The Arrhenius plot and extracted parameters are displayed in Fig 3.
Free EGF and EGF conjugated HAOA—coated gold nanoparticles fluorescencekinetics
(em. at 330 nm) upon 295 nm excitation. Fluorescence emission intensity kinetic traces at
Table 2. Single exponential fit using model F(t) = C1*exp(-x*k1) + y0 for each decay curve of EGF at 10˚C, 15˚C, 20˚C and 30˚C. For the decay curve
of EGF at 25˚C, a double exponential fit using model F(t) = y0+C1*exp(-k1*x)+C2*exp(-k2*x) was selected (see Fig 2A). Fit parameters are displayed in this
table. Adj. R2 stands for Adjusted R- Square.
Decay Parameters Statistic
y0 C1 C2 k1 k2 Adj. R2
10˚C 7.1E+4±1.5E+2 1.0E+6±1.4E+2 - 1.1E+3±4.7 - 0.999
15˚C 7.2E+4±1.5E+2 9.8E+4±1.4E+2 - 1.1E+3±6.2 - 0.999
20˚C 7.7E+4±2.0E+2 1.2E+5±2.4E+2 - 2.2E+3±1.3E+1 - 0.999
25˚C 5.6E+4±3.9E+2 4.3E+4±5.9E+2 7.1E+4±3.1E+2 2.8E+2±4.1 1.7E+3±3.0E+1 0.999
30˚C 6.3E+4±1.7E+2 9.0E+4±2.8E+2 - 7.5E+2±5.9 - 0.997
doi:10.1371/journal.pone.0165419.t002
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330 nm for free EGF, plain non-coated gold nanoparticles, HAOA-coated gold nanoparticles
and EGF-conjugated HAOA-coated gold nanoparticles samples are displayed in Fig 5. Traces
were acquired upon continuous 295 nm illumination for 2 hours, at 20°C, except for plain gold
nanoparticles and HAOA-coated gold nanoparticles without EGF, which were illuminated for
1 hour. All traces were fitted using a double exponential decay model according to the formula
F(t) = y0+C1exp(-k1x)+C2exp(-k2x). F(t) is the fluorescence emission intensity at 330 nm
(a.u.) upon 295 nm excitation at time t (min), y0, C1 and C2 are constants and k1 and k2 is
the rate constant of fluorescence emission intensity decrease (min-1); y0 value was fixed to 0.
The root mean square error R2 was> 0.99 for all kinetics. The fitted parameter values and cor-
responding errors, and root mean square error values obtained after fitting the 330 nm emis-
sion kinetic traces are displayed in Table 4.
Results
Although EGF is formed by two amino acid chains (A and B), only chain B is represented in
Fig 1. In total, EGF has 2 Trp residues, 5 Tyr residues and 3 SS bridges. Table 1 lists the shortest
distances between each Trp and Tyr residues and the nearest SS bonds. The shortest distance
betweenTyr13 (atom CD1) and the SS bridge C14-C31 is 4.4 Å. All considered distances
were< 12 Å. In addition, EGF has no Phenylalanine (Phe) residues but has a considerable
number of Arginine (Arg) residues in its structure, close to Trp residues. Arg residues are of
Table 3. Single exponential fit using model F(t) = C1*exp(-x*k1) + y0 for each decay curve of EGF at a power slit size of 0.5 mm and 0.8 mm (corre-
sponding to 0.30 μW and 1.67 μW, respectively) and double exponential fit using model F(t) = y0+C1*exp(-k1*x)+C2*exp(-k2*x) for each decay
curve of EGF at a power slit size of 1.2 mm and 2.0 mm (corresponding to 2.34 μW and 4.40 μW, respectively) (see Fig 4A). For slit 0.1 mm
(0.12 μW), a linear model was selected. Fit parameters are displayed in this table. R2 stands for Adjusted R- Square.
Slit(mm) Decay Parameters Statistic
y0 C1 C2 k1 k2 R2
0.1 1.8 E+4±1.1E+1 -0.16±2.7E-3 - - - 0.921
0.5 5.7E+4±1.2E+2 6.2E+4±1.0E+2 - 3.0E+4±1.5E+1 - 0.999
0.8 7.7E+4±2.0E+2 1.2E+5±2.4E+2 - 2.2E+3±1.3E+1 - 0.999
1.2 5.8E+4±1.1E+4 9.0E+4±5.6E+3 1.2E+5±5.5E+3 7.9E+3±2.1E+3 1.2E+3±3.7E+1 0.999
2.0 9.8E+4±1.8E+3 2.2E+5±1.3E+3 1.2E+5±6.4E+2 6.8E+2±4.9 5.1E+3±2.1E+2 0.999
doi:10.1371/journal.pone.0165419.t003
Table 4. Double exponential fit using model F(t) = yo+C1*exp(-k1*x)+C2*exp(-k2*x) for free EGF, EGF-conjugated HAOA-coated GNP (gold nano-
particles), plain non-coated GNP (control) and HAOA-coated GNP (control) (see Fig 5). Fit parameters are displayed in this table. Adj. R2 stands for
Adjusted R- Square.
Samples Constants (y0, k1, k2) Adj. R2 Pre-exponential factors (C1, C2)
Free EGF • y0 = 9.8E+4 ± 1.8E+3
• k1 = 6.8E+2 ± 4.9
• k2 = 5.1E+3 ± 2.1E+2
0.999 • C1 = 2.2E+5 ± 1.3E+3
• C2 = 1.2E+5 ± 6.4E+2
EGF—conjugated HAOA GNP • y0 = 1.2E+5 ± 4.4E+2
• k1 = 4.3E+2 ± 1.8E+1
• k2 = 3.9E+3 ± 2.3E+2
0.996 • C1 = 1.8E+4 ± 4.4E+2
• C2 = 2.2E+4 ± 2.2E+2
Plain non-coated GNP (control) • y0 = 7.7E+4 ± 1.0E+3
• k1 = 5.7E+2 ± 5.2E+1
• k2 = 6.5E+3 ± 5.2E+2
0.997 • C1 = 6.2E+3 ± 3.7E+2
• C2 = 2.6E+4 ± 6.6E+2
HAOA-coated GNP(control) • y0 = 8.9E+4 ± 1.0E+3
• k1 = 3.5E+2 ± 8.7E+1
• k2 = 7.6E+3 ± 7.1E+2
0.989 • C1 = 2.1E+3 ± 2.6E+2
• C2 = 1.8E+4 ± 8.1E+2
doi:10.1371/journal.pone.0165419.t004
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considerable importance since they quench the aromatic residues fluorescence emission, when
the NH2 groups become protonated. The closest distances between these two amino acids
occur betweenArg45 (NE) and Trp50 (CH2) and Trp49 (CE3) at 4.5 Å and 7.5 Å, respectively.
Firstly, the behavior of the free peptide to temperature and light exposure was assessed. Fig
2A and 2B display the fluorescence kinetic traces for EGF upon 2 hours excitation at 295 nm
(emission fixed at 330 nm) and for SYPRO1 Orange an analogous experiment (excitation of
470 nm and emission fixed at 580 nm), respectively. At all acquired temperatures, fluorescence
emission intensity of Trp is observed to decay as a function of illumination time. On the other
hand, fluorescence emission intensity of SYPRO1 Orange increases with illumination time. At
10°C and 15°C, EGF showed similar fluorescence emission decays with a decrease in Trp fluo-
rescence emission intensity at 330 nm of 56.2%, 52.8%, respectively. The corresponding
increase in the fluorescence emission of SYPRO1 Orange after 2 hours excitation of EGF at
295 nm at 10°C and 15°C was 15.6% and 22.7%, respectively. At 20°C and 30°C, the fluores-
cence emission intensity of Trp decreased 59.6% and 59.1%, respectively, after 2 hours excita-
tion of EGF at 295 nm, while the fluorescence emission intensity of SYPRO1 Orange increased
2.3% and 17.3%, respectively. At last, continuous 295 nm excitation of EGF at 25°C led to a
59.7% decrease in the fluorescence emission intensity of the protein and to a 6.7% increase in
the fluorescence emission intensity of SYPRO1 Orange. When exposing free EGF to five dif-
ferent temperatures, an Arrhenius plot was obtained, as displayed in Fig 3. Due to the tempera-
ture dependence of the EGF rate constant (k), recovered from the fluorescence emission decays
at 330 nm (excitation at 295 nm), we obtained an activation energy (Ea) and a pre-exponential
factor (A0) of 19.9±0.9 kJ.mol-1 and 0.44±0.37 s-1, respectively. The equation obtained was
y = -1.1x − 1933.4 (R2 = 0.994).
The kinetic traces for free EGF during 2 hours excitation at 295 nm (emission at 330 nm) at
20°C and the kinetic traces for SYPRO1 Orange (excitation of 470 nm and emission at 580
nm) using different excitation powers are displayed in Fig 4A and 4B. Excitation of free EGF at
295 nm for 2 hours with different excitation slit sizes of 0.1 mm, 0.5 mm, 0.8 mm, 1.2 mm and
2.0 mm led to a 8.0%, 48.6%, 59.6%, 65.6% and 70.8% decrease in Trp fluorescence emission
intensity, respectively. After 295 nm excitation of EGF for 2 hours, the fluorescence emission
intensity of SYPRO1 Orange increases 9.1%, 2.3%, 21.5% and 6.1% for slit sizes of 0.5 mm, 0.8
mm, 1.2 mm and 2.0 mm, respectively. In the same experiments, the fluoresce emission inten-
sity of SYPRO1 Orange has maximally increased by 9.1%, 3.2%, 26.8% and 19.3% for 0.5 mm,
0.8 mm, 1.2 mm and 2.0 mm, respectively. No change was observed in the fluorescence emis-
sion intensity of SYPRO1 Orange at a slit size of 0.1 mm (decrease: 0.2% = ~0%). A single
exponential model (F(t) = y0 +C1exp(-xk1)) was selected to fit the 330 nm decay curves
obtained with 0.5 mm and 0.8 mm slit openings. The traces obtained with larger slit openings
(1.2 mm and 2.0 mm) were fitted with a double exponential model (F(t) = y0+C1exp(-k1x)
+C2exp(-k2x)). The corresponding fitted parameter values (C1, C2 k1, k2, y0) and correspond-
ing errors, as well as root mean square error values, are displayed in Table 3. The 330 nm fluo-
rescence decay obtained when a slit 0.1 mmwas chosen was best fitted by a linear model.
After studying the temperature and power dependence of the kinetic traces for free EGF, the
behavior of this peptide has beenmonitored after conjugation with a nanosystemmade of a
gold core and a biodegradable polymeric coating of hyaluronic and oleic acids (HAOA).
HAOA-coated gold nanoparticles (i.e., non-conjugated with EGF) showed a mean particle size
of 300 nm (PI: 0.2) and a negatively charged surface (-19 mV) [24]. After conjugation with
EGF, the volume distribution for 90% of HAOA-coated gold nanoparticles (D 90%) was 220
nm, as confirmed by TEM analysis, where EGF-conjugated HAOA-coated gold nanoparticles
showed a size around 100–200 nm and a spherical morphology (see Fig 5). EGF-conjugated
HAOA-coated gold nanoparticles are composed by a dense gold core observed in the TEM
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image as a dark core, and by a soft polymeric coating of HAOA on the surface, visible in the
TEM image as a grey area around the core. EGFmay be associated to the HAOA coating of the
gold nanoparticles as illustrated in Fig 5. Zeta potential (ZP) of EGF-conjugated HAOA-coated
gold nanoparticles was around -5 mV when compared to the lower value of -19 mV for the
HAOA-coated gold nanoparticles alone. In addition, a maximum absorbance peak at 655 nm
compared to 800 nm observed for the plain non-coated gold nanoparticles, indicating that a
145 nm blue shift has occurred after conjugation.
The EGF fluorescence emission intensity at 330 nm during 2 hours of continuous 295 nm
excitation is displayed in Fig 6 and compared for free EGF, EGF-conjugated HAOA-coated
gold nanoparticles, empty HAOA—coated gold nanoparticles and non-coated plain gold nano-
particles. Plain gold nanoparticles (i.e., without HAOA coating) and HAOA-coated gold nano-
particles were used as controls. The double exponential fit model (F(t) = yo+C1exp(-k1x)
+C2exp(-k2x)) used to fit the kinetic traces for free EGF and EGF-conjugated HAOA-coated
gold nanoparticles showed that the fluorescence emission intensity of free EGF decayed faster
than the one for conjugated EGF with HAOA-coated gold nanoparticles. Decay constants for
conjugated EGF were 1.5-fold (k1) and 1.3-fold (k2) lower compared to the ones for free EGF.
Also, the initial Trp 330 nm fluorescence emission intensity (excitation at 295 nm) for EGF-
conjugated HAOA-coated gold nanoparticles is almost three times lower than the initial fluo-
rescence emission intensity of free EGF. Fitting results are represented in Table 4.
Afterwards, the effect of conjugation on the fluorescence spectra of EGF was investigated.
Fluorescence excitation spectra (emission fixed at 330 nm) and fluorescence emission spectra
(excitation fixed at 295 nm) were compared for free EGF in supernatant, EGF-conjugated
HAOA—coated gold nanoparticles (before centrifugation) and EGF-conjugated HAOA—
coated gold nanoparticles (after centrifugation) (see Fig 7A). Centrifugation at 500 x g for 20
min was essential for the elimination of the non-conjugated EGF and EGF was only illumi-
nated with the light necessary for obtaining the represented spectra. Isolated EGF-conjugated
HAOA—coated gold nanoparticles (after centrifugation) showed a clear emission peak at 326
nm, which confirms the presence of Trp residues at the HAOA—coated gold nanoparticles’
surface (see Fig 7B).
Figs 8 and 9 display the fluorescence excitation and emission spectra of EGF, as free peptide
and as conjugated with HAOA-coated gold nanoparticles, and of SYPRO1 Orange. The fluo-
rescence emission and excitation intensity of SYPRO1 Orange is 10 and 18.6 higher, respec-
tively, when added to EGF-conjugated HAOA-coated gold nanoparticles than when added to
free EGF. Fluorescence emission intensity of free EGF at 328 nm decreased 74.8%, after illumi-
nation, and a blue shift occurred from 344 nm to 328 nm, while the fluorescence emission
intensity of EGF-conjugated HAOA-coated gold nanoparticles at 347 nm decreased 25.7%. As
for the fluorescence emission intensity of SYPRO1 Orange, the values decreased 21.4% and
23.8% after illumination of both free EGF and EGF-conjugated HAOA-coated gold nanoparti-
cles, respectively. Interestingly, the fluorescence emission spectra of SYPRO1 Orange showed
a blue shift (from 610 nm to 594 nm) when added to free EGF, while when added to EGF-con-
jugated HAOA-coated gold nanoparticles, the peak of SYPRO1 Orange emission spectra
showed a red shift from 584 nm to 628 nm (see Fig 9).
In order to detect the putative presence of photochemical species such as NFK and Kyn,
fluorescence emission spectra upon 320 nm excitation were acquired for free EGF and for
EGF-conjugated HAOA-coated gold nanoparticles, before and after 295 nm continuous illumi-
nation of the samples (see Fig 10A). HAOA-coated gold nanoparticles spectra, before and after
2 hours illumination at 295 nm, were used as controls. For free EGF, a peak centered at 418
nm was observedupon 320 nm excitation. The fluorescence emission intensity of the peak
increases 51.0% after continuous excitation with 295 nm for 2 hours. For EGF-conjugated
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HAOA-coated gold nanoparticles, two peaks were observed: a peak centered at 392 nm and a
larger peak at 598 nm. The second peak at 596–598 nm is also visible for the controls HAOA-
coated gold nanoparticles, without EGF, before and after continuous illumination, though 3 to
4 times less intense. After continuous excitation with 295 nm for 2 hours, the fluorescence
emission intensity decreased by 14.8% and 5.8%, for the peak centered at 392 nm and 598 nm,
respectively. In Fig 10B are displayed the fluorescence emission intensity spectra upon 360 nm
excitation in order to detect the putative presence of the photochemical species Kyn and NFK.
HAOA-coated gold nanoparticles spectra, before and after 2 hours illumination at 295 nm,
were used as controls. For free EGF, a peak centered at 460 nm is observedupon 360 nm excita-
tion. The fluorescence emission intensity of the peak increases 127% after continuous excita-
tion with 295 nm for 2 hours. Two emission peaks were observed for EGF-conjugated HAOA-
coated gold nanoparticles: a peak centered at 461 nm and a larger peak at 580 nm. The second
peak at 580 nm is also visible for the control HAOA-coated gold nanoparticles, without EGF,
before and after continuous illumination, but with less intensity, like observedupon 320 nm
excitation. After continuous excitation with 295 nm for 2 hours, the fluorescence emission
intensity decreased by 5.7% and 40.8%, for the peak centered at 461 nm and 580 nm,
respectively.
In order to characterize the binding of EGF to HAOA-coated gold nanoparticles, colocali-
zation experiments were conducted in a confocal microscope (Fig 11; scale bar at 5 μm). EGF
labeled with Alexa Fluor 647 appears in red and HAOA-coated gold nanoparticles labeled
with Coumarin-6 appear in green; EGF-conjugated HAOA-coated gold nanoparticles is dis-
played in yellow. On the other hand, circular dichroism (CD) is a goodmethod to evaluate
changes in the secondary structure of proteins, after binding. Fig 12 shows far UV CD spectra
collected for different samples. The spectra show that after conjugation with HAOA-coated
gold nanoparticles EGF maintains its secondary structure. Although free EGF (non conju-
gated) has a signal of higher intensity than the rest of the studied samples (i.e., EGF-conju-
gated HAOA-coated gold nanoparticles, EGF in supernatant and extracted EGF with acidic
pH solution), its concentration was also 18 times higher. The CD spectra indicate that EGF
probably has a secondary structure, with contributions from different secondary elements.
This is suggested by the presence of a negative peak around 208–210 nm, characteristic of α-
helix structure. However, the negative band at 220 nm, also characteristic of α-helix structure
was not detected. The absence of CD bands above 215–220 nm range suggests the presence of
EGF’s β- sheets.
Finally, cell culture experiments allowed us to understand how the nanoparticles interact
with in vitro biological systems. When exposing human keratinocytes (HaCaT) to EGF-conju-
gated HAOA-coated nanoparticles for 24 hours, no aggregates were visible after addition of the
nanoparticles to the plaque wells (Fig 13). In addition, EGF-conjugated HAOA-coated gold
nanoparticles at 80 μM the highest concentration tested, showed a cell viability of around 75%
of that of non-treated control cultures. As for the experiments for the EGFR binding assay car-
ried out with human lung carcinoma A549 cells, images were taken 1.5 hours after the cells
being in contact with EGF and for the negative control (Fig 14). Three different samples were
tested: free EGF labeled with Alexa Fluor 647 (A1); EGF-conjugated HAOA-coated gold nano-
particles, being EGF labeled with Alexa Fluor 647 (B1); and EGF-conjugated HAOA-coated
gold nanoparticles, with EGF labeled with Alexa Fluor 647 and the HAOA-coated gold nano-
particles labeled with Coumarin-6 (C1). In addition, the same samples were tested after the
cells were incubated for 1 hour with anti-EGFR antibody, in order to block the EGF receptors.
Finally, two control groups were studied: CN1, corresponding to cells from the non-treated
group (i.e., cells without the addition of EGF or nanoparticles and of the anti-EGFR antibody)
and CN2, corresponding cells in presence of HAOA-coated gold nanoparticles (without dye or
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EGF conjugation). In panels A1, B1 and C1 it can be observed that EGF has induced EGFR
internalization, alone and when conjugated with the HAOA-coated gold nanoparticles. Both
free EGF and EGF-conjugated HAOA-coated gold nanoparticles (panels B1 and C1) entered
the cells’ cytoplasm but not its nucleus. The anti-EGFR antibody blocked the binding of EGF
to EGFR, preventing receptor internalization (panel A2); however, the EGF-conjugated
HAOA-coated gold nanoparticles could still enter the cells (panels B2 and C2) despite the pres-
ence of the antibody. The controls (panels CN1 and CN2) confirm that in the absence of EGF
and in the absence of nanoparticles there is no EGFR activation.
Discussion
The presented data has shown that the structure of EGF (Fig 1) can bemodulated by UV-light
(295 nm) and that the photochemical changes are reduced when EGF is bound to HAOA-
coated gold nanoparticles (Fig 6). Like other small proteins and peptides (e.g., cutinase, insulin,
α-lactoalbumin) [14,17,31], EGF is an interesting model protein for photostability studies due
to the close spatial proximity between its aromatic residues and its disulphide (SS) bridges. SS
bridges are key structural elements in small proteins [31], responsible for maintaining the pro-
teins´ structure and therefore their function.Disruption of SS bonds induced by UV excitation
of aromatic residues in those peptides will most likely destroy its structure and impair its func-
tion [14,17,31]. Table 1 lists the three SS bonds of EGF located in close spatial proximity to aro-
matic residues (Trp and Tyr). The observed close distances will allow for electron transfer
between the aromatic residues and the SS bridges [17], leading to the disruption of such brid-
ges. EGF is a protein where these reactions will occur in the presence of UVB light leading to
protein conformational changes and to loss of functionality. EGF is a natural ligand for EGFR
with significant biomedical importance in cancer treatment and diagnostic [19]. Changes in
the fluorescence spectra of the extrinsic fluorescence probe SYPRO1 Orange confirmed struc-
tural changes of EGF induced by temperature (Fig 2), prolonged illumination at 295 nm (Fig 4)
and pH, as its fluorescent emission is enhanced upon binding to hydrophobic regions of the
protein [20]. Temperature-dependent time based photochemical studies (see Fig 2A) show that
EGF photochemistry and protein conformational space is temperature dependent, being simi-
lar at 10°C and 15°C, at 20°C and 30°C but distinct at 25°C. At 25°C, SYPRO1 Orange appears
to bind less to the peptide than at other temperatures, indicating that EGF has fewer hydropho-
bic surfaces exposed to the solvent. The Arrhenius plot (see Fig 3) showed that the activation
energy (Ea) associated with the photochemical reactions induced by 295 nm on EGF was 19.9
±0.9 kJ.mol-1 (i.e., 4.76 kcal/mol). This value was similar to the one found for α-lactalbumin
(Ea = 21.8±2.3 kJ.mol−1) [31]. Power-dependent irradiation studies of EGF (see Fig 4A) reveal
that the larger the power used, the faster the kinetics associated with the fluorescence decays. A
single exponential model was used to fit the Trp decay curves acquired with 0.30 μW and
1.67 μW (see Table 3) but for larger powers (2.34 μW and 4.40 μW) a double exponential
model was needed. This shows that different photochemical processes are initiated at higher
powers when compared to lower powers. Experiments carried out with SYPRO1 Orange (see
Fig 4B) show the same trend. Conformational changes induced in EGF are larger when illumi-
nation was carried out with higher powers: when using a 2.0 mm slit size opening, the fluores-
cence emission intensity of SYPRO1 Orange was higher than when working with a 0.1 mm
slit, indicating that the extrinsic probe is in contact with a larger hydrophobic surface rendered
accessible due to light induced conformational changes.
Conjugation of EGF to HAOA-gold nanoparticles protected EGF from photochemistry (Fig
6, Table 4): the presence of the particles decreased the rate of the light induced fluorescence
changes and induced quenching. Both HA, OA and gold are known to be fluorescence
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quenchers. EGF has a promising therapeutic value as a targeting ligand for tumours overex-
pressing EGFR, such as melanoma [32]. Therefore, it has been coupled to nano-sized delivery
systems, made of either and both metallic and polymericmaterials [33,34]. The photochemical
protection conferred by nanoparticulate carriers is advantageous.
Gold nanoparticles were prepared according to a seed-growthmethod [21,35]. An aqueous
extract of Plectranthus saccatus (Benth.), rich in anti-oxidative compounds (e.g., rosmarinic
acid, caffeic acid and chlorogenic acid [36]), was used as the main reducing and capping agent.
Furthermore, a coating made of hyaluronic and oleic acids (HAOA) was added to the gold
nanoparticles. Natural polymers can work as reducing and capping agents, activating “green”
reduction of gold and being less toxic for healthy tissues, which make them advantageous in
the reduction and morphology of gold nanoparticles [35,37]. Furthermore, the use of poly-
meric coatings is also interesting as a way to control drug release and to increase the adsorption
of ligands. Recently, Su et al. (2014) showed that hyaluronic acid (HA) scaffolds can increase
the adsorption and sustained release of EGF, attached to the polymeric surface through self-
assembly and electrostatic interactions [38]. In addition, HA is reported to confer structural
stability to proteins [12]. Herein, we studied the effect of mounting EGF to HAOA-coated gold
nanoparticles. In Fig 5, it can be observed that EGF-conjugated HAOA-coated gold nanoparti-
cles show the gold core (dark core) surrounded by HAOA polymer. On the upper left corner of
Fig 5 is displayed a model of the EGF-conjugated HAOA-coated gold nanoparticles. Kinetic
data displayed in Table 4 and Fig 6 confirms that the polymers and the gold core promoted
protein quenching and induced slower decay kinetics when compared with the data obtained
with free EGF, protecting EGF from photochemistry. The same has been reported by Oliveira
Silva et al. (2015) when studying the photochemistry of free lysozyme and comparing it to the
photochemistry of lysozymemounted onto HAOA-coated gold nanoparticles [23]. It is likely
that the structure of EGF, after conjugation to HAOA-coated nanoparticles, sustains excitation
at 295 nm for longer time periods, prior to possible loss of structure and function. The presence
of EGF conjugated to the HAOA-coated gold nanoparticles was confirmed by fluorescence
spectroscopy, after centrifugation and re-suspension with PBS, demonstrating a clear emission
peak at 326 nm for Trp residues (Fig 7). The conjugation of EGF onto HAOA-coated gold
nanoparticles conferred enhanced photostability to EGF. This is observed in Fig 8, where a
smaller intensity reduction occurs in both fluorescence excitation spectra (41.0% versus 81.2%)
and fluorescence emission spectra (25.7% versus 74.8%), after 295 nm continuous illumination.
Furthermore, the observedblue shift in the fluorescence emission spectra of free EGF, after 295
nm continuous illumination, is no longer visible for EGF-conjugated HAOA-coated gold
nanoparticles (Fig 8). This is probably due to the fact that conjugation of EGF has prevented
conformational changes that rendered the Trp moieties more apolar, responsible for the blue
shift. SYPRO1 Orange was used as an extrinsic probe for monitoring UV-light (295 nm)
induced conformational changes in EGF (Fig 9). Firstly, it was observed that SYPRO1 Orange
showed affinity towards hydrophobic moieties in HAOA-coated gold nanoparticles, leading to
an increase of its fluorescence emission intensity signal compared to its fluorescence emission
intensity in free EGF solution (Fig 9). Secondly, the fluorescence emission spectra of EGF-con-
jugated HAOA-coated nanoparticles suffered a red shift (from 584 nm to 638 nm) after 2
hours of continuous 295 nm illumination. On the other hand, the fluorescence emission spec-
tra of free EGF suffered a blue shift (from 610 nm to 594 nm) after 2 hours of continuous 295
nm illumination. The observed red shift for SYPRO1 Orange reveals that the probe is in a
more polar environment after illumination.
Finally, the antioxidant compounds of Plectranthus saccatus, present in the HAOA-coated
nanoparticles formulation, can also have an important role in protecting EGF from light
induced reactions. Phenolic compounds are highly present in natural plant extracts and are
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described to show anti-oxidant effects on Trp oxidation and to be fluorescence quenchers [39].
It has been shown that the oxidation of the indole ring of Trp can be inhibited and, conse-
quently, the formation of NFK and Kyn, by associating proteins with phenolic compounds
from natural plant extracts [39, 40]. This is positively correlated with our data. Conjugation of
EGF to HAOA-coated gold nanoparticles reduced or even avoided the formation of photo-
products such as NFK and Kyn (see Fig 10A and 10B).
The presence of oxidative conditions induced by light can lead to the oxidation of the aro-
matic residues in proteins [14,15,19,31,41]. UVB excitation of aromatic residues in proteins
leads to the disruption of SS bridges [14–17,19] and to the formation of photoproducts, such as
N-formylkynurenine (NFK), kynurenine (Kyn) [25,42] and dityrosine (DT) [26]. Since 295 nm
excites specificallyTrp residues, it is very likely that the photoproducts formed are Trp deriva-
tives such as NFK and Kyn and not Tyr derivatives like DT. Furthermore, the emission spec-
trum of EGF upon 295 nm leads to a fluorescence emission spectrumthat peaks around 330
nm, whichmakes it unlikely that Tyr residues will be excited by EGF emission. Two excitation
wavelengths were used in order to detect the presence of photochemical products: 320 nm (Fig
10A) and 360 nm (Fig 10B). Light at 320 nm excites both NFK (εNFK(321nm) = 3750 M-1cm-1)
[42–45] and Kyn (εKyn(321nm) = 1812 M-1cm-1) [46]. At 315 nmDT has an extinction coefficient
equal to 5200 M-1cm-1 but, as explained above, it is unlikely that it has been formed [47,48].
Light at 360 nm excites NFK (εNFK(360nm) = 1607 M-1cm-1 [46] and Kyn (εKyn(365nm) = 4530
M-1cm-1 [49,50]) but does not excite DT. In Fig 10A, the peak with maximum fluorescence
emission intensity (320 nm excitation) for free EGF occurs at 418 nm and for EGF-conjugated
HAOA-coated occurs at 392 nm. In Fig 10B, the peak with maximum fluorescence emission
intensity (360 nm excitation) for free EGF occurs at 460 nm and for EGF-conjugated HAOA-
coated nanoparticles it is seen at 461 nm. This peak cannot belong to DT, since DT is not excited
at 360 nm. Therefore, it can be Kyn since the wavelength of maximum fluorescence emission of
Kyn lies within 434–480 nm.
Colocalization experiments carried out with confocal fluorescencemicroscopy (Fig 11) con-
firmed that EGF (red colour) appears to be associated and colocalizedwith HAOA-coated gold
nanoparticles (green colour), which can be visualized as yellow coloured spots. Since EGF
shows a pI around 4.55 and HAOA-coated gold nanoparticles have a superficial negative
charge (-19 mV), attractive electrostatic interaction between the protein and the nanocarrier
are not likely to occur at pH 7.4. In spite of this, a slight increase of the nanoparticles’ surface
charge after EGF conjugation (-5 mV) is observed and, as already mentioned, the peptide con-
jugation onto the particles has also been confirmed by fluorescence spectroscopy. Moreover,
literature described that EGF is likely to be associated to hyaluronic acid (HA) scaffolds
through the polymer’s carboxylic groups and since HA is a hydrogel with high hygroscopic
character, interactions between EGF and the polymer can occur by hydrophilic interactions
[12,38,51]. Another possible mechanism for EGF conjugation onto HAOA-coated gold nano-
particles is by means of binding between an amino acid residue of the peptide and the HAOA
coating or gold core. Histidine has been described as a very strong metal binding amino acid
[52]. EGF has two histidine residues (His10 and His16). Lysine residues (Lys28 and Lys48) of
EGF were also pointed out as a potential binding site for EGF conjugation with HA polymer
[53], especially Lys48, which is located at the end of lateral chain of EGF.
Far UV spectra for CD showed that EGFmaintained its non-helical, random coil structure,
before and after conjugation and after extraction from the HAOA-coated gold nanoparticles,
when incubated at 37°C in pH 5.5 phosphate buffer (Fig 12). The native structure of EGF is
described to be mainly composed of random coil elements (72%) and β-helical elements (25%)
and only a trace of α-helical content [3]. The random coil secondary structure contributes to
the presence of a negative peak at 200–210 nm [54]. Although a typical shoulder formation at
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220 nm is described for EGF [54], as indicative of the presence of random non-helical forms
and β-sheets, spectra with a flat curve around 215–225 nm is also expected for EGF, suggesting
a low content on β forms [55]. It has been observed this flat curvature for all spectra of EGF
samples above 215–220 nm (Fig 12). EGF-conjugated HAOA-coated gold nanoparticles
showed a negative peak at 208 nm, as free EGF in its native form, in PBS pH 7.4. However, a
spectral blue shift was detected for both EGF in supernatant, as for the unbound peptide,
recovered after centrifugation of the EGF-conjugated HAOA-coated nanoparticles and EGF
extracted after incubation of EGF-conjugated HAOA-coated gold nanoparticles in phosphate
buffer pH 5.5, at 37°C, for 72 hours. Both EGF in the supernatant and extracted EGF’s peaks
shifted to 206 nm. Furthermore, HAOA-coated gold nanoparticles, without EGF, showed an
intense signal for the main negative peak at 200–210 nm, with a minimum at 201 nm, which
can be due to the fact that HAOA coating of gold nanoparticles, especially HA, also absorb in
the far UV range [56].
After characterizing the EGF-conjugated HAOA-coated gold nanoparticles in terms of
pharmaceutical technology and protein stability, its potential biological application was evalu-
ated. Firstly, the cell viability in normal-like human keratinocytes (HaCaT cell line) was tested
in order to verify if our nanoparticles were safe when in contact with a healthy non-cancer tis-
sue (see Fig 13). Statistical analysis was based on Student’s t-test for comparisons between cell
viability values with non-conjugated HAOA-coated gold nanoparticles [21] and EGF-conju-
gated HAOA-coated nanoparticles (present work). No significant differences (p> 0.05) were
found between the viability of HaCat cells treated with HAOA-coated gold nanoparticles and
EGF-conjugated HAOA-coated gold nanoparticles at equal concentrations. Finally, when test-
ing the biologic activity of EGF-conjugated HAOA-coated nanoparticles, compared to free
EGF, for EGFR binding, we have used a well-studied cell model for describedpreviously for
Human EGFR Live Cell Fluorescent Biosensor Assay [30]. Therefore, it was observed that both
peptides, in those different conditions, were able to bind to the receptor and activate its inter-
nalization (visible green fluorescence as shown in Fig 14), making possible downstream signal
transduction. It has been observed in our study that the antibody anti-EGFR competitively
inhibits the binding of free EGF to EGFR, but not for EGF-conjugated to HAOA-coated gold
nanoparticles. Therefore, nanoparticles can also enter the A549 cells by a putative different
internalization mechanism than EGFR-modulated internalization. EGF-conjugated HAOA-
coated gold nanoparticles may modulate the endocytic pathways for entering the cells. One
example is the use of other cell receptors, such as CD44, for which hyaluronic acid is a specific
ligand, which are also described to be also overexpressed in many solid tumor cells including
breast, melanoma and lung cancer, like the A549 cell model used in this study [57,58]. Qhattal
et al. (2011) confirmed this possibility when they demonstrated by fluorescencemicroscopy
that HA-coated liposomes, made of high-molecularweight HA, led to increased uptake of lipo-
somes by A549 cells, with high and irreversible binding affinity [59]. As observed in Fig 14,
EGF-conjugated HAOA-coated gold nanoparticles accumulate around the peri-nuclear area,
but do not penetrate into the cell nucleus, after 1.5 hours-incubation.Wang et al. (2013)
showed that lipid-coated gold nanoparticles promoted the formation of acidic compartments,
which appear to be lamellar bodies, in A549 cells [60]. These vesicles appear to internalize the
nanoparticles, allowing them to enter the cell. Wang et al. (2013) also state that internalization
occurs as a result of the negative charge of gold nanoparticles penetrating the lung surfactant,
which primarily contains a mixture of phosphatidyl choline and phosphatidyl glycerol lipids
[60]. Other polymeric coated gold nanoparticles, also highly negatively charged (-40 mV) were
retained in the endolysosomal compartments, also predominant presence at the perinuclear
region, after 1 and 2 hours-incubation with A549 cells [61]. This internalization was reported
to occur very quickly, around 1 hour to 2 hours, probably due to EGF small size and high
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affinity to EGFR.Maybe, as a consequence, the clearance is also faster in lysosomes and in cells
with high expression of EGFR [62]. Finally, another study using A549 lung cancer cells, sulfhy-
dryl-activatedEGF conjugation with lipidic nanoparticles were colocalizedwith the labeled
EGF receptors and the internalization of EGF-conjugated nanoparticles was visible [33].
In conclusion, the EGF-conjugated HAOA-coated gold nanoparticles developed in this
work show a potential application for near infrared (NIR, 650–800 nm) photothermal therapy,
which may efficiently destroy cancer cells. NIR photothermal therapy reduces the damage of
the healthy tissue compared to visible photothermal therapy, as the optical radiation is the low-
est absorbed by the human tissue [1]. HAOA-coated gold nanoparticles protected EGF from
295 nm induced photochemistry and did not induce EGF denaturation, reducing the formation
of photoproducts such as NFK and Kyn. Moreover, EGF-conjugated HAOA-coated nanoparti-
cles did not markedly decreaseHaCaT cell viability, showing high biocompatibility with
healthy tissues, and were able to enter the EGFR-overexpressing tumor cell line A549, by differ-
ent internalization mechanisms. As future prospects, cancer treatment could benefit from a
combined approach, using multiple targeting moieties, for a specific cancer cell pool and acting
by several molecular pathways. Another advantage would be the conjugation of a light-absorb-
ing core, for photothermal therapy, and a polymeric coating, capable of promoting the incor-
poration of anticancer drugs, for a local chemotherapy.
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